This report discusses a case of neovascular age-related macular degeneration with mixed serous pigment epithelial detachment (PED) that was unresponsive to antivascular endothelial growth injections but responded to the addition of intravitreal steroid injection.
Methods:
We report a case.
Results:
A 75-year-old woman with neovascular age-related macular degeneration developed a mixed serous PED in her right eye. Three monthly aflibercept (Eylea, Regeneron) treatments led to resolution of associated intraretinal fluid; however, the mixed serous and fibrovascular PED significantly increased in size. The addition of intravitreal dexamethasone (Ozurdex, Allergan) to monthly aflibercept led to prompt flattening of the PED. Three months later, the PED recurred despite continued administration of monthly aflibercept.
Conclusions:
This case supports a growing body of research that PEDs unresponsive to antivascular endothelial growth injections may respond to intravitreal steroid injections.
GassJD. Drusen and disciform macular detachment and degeneration. Trans Am Ophthalmol Soc. 1972;70:409–436. doi:10.1001/archopt.1973.01000050208006
2.
SarrafDJosephARahimyE. Retinal pigment epithelial tears in the era of intravitreal pharmacotherapy: risk factors, pathogenesis, prognosis and treatment (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc. 2014;112:142–159.
3.
LommatzschAHeimesBGutfleischMSpitalGZeimerMPauleikhoffD. Serous pigment epithelial detachment in age-related macular degeneration: comparison of different treatments. Eye (Lond). 2009;23(12):2163–2168. doi:10.1038/eye.2008.425
4.
GonzalezAKhurshidG. Treatment of retinal pigment epithelial detachment secondary to exudative age-related macular degeneration. Am J Ophthalmol Case Rep. 2018;9:18–22. doi:10.1016/j.ajoc.2017.12.004
5.
ParkDHSunHJLeeSJ. A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration. Int Ophthalmol. 2017;37(5):1205–1214. doi:10.1007/s10792-016-0391-4
6.
WilloughbyASYingGSTothCA, et al.Subretinal hyperreflective material in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2015;122(9):1846–1853.e5. doi:10.1016/j.ophtha.2015.05.042
7.
KauppinenAPaternoJJBlasiakJSalminenAKaarnirantaK. Inflammation and its role in age-related macular degeneration. Cell Mol Life Sci. 2016;73(9):1765–1786. doi:10.1007/s00018-016-2147-8
8.
WhitcupSMSodhiAAtkinsonJP, et al.The role of the immune response in age-related macular degeneration. Int J Inflam. 2013;2013:348092. doi:10.1155/2013/348092
9.
ParmeggianiFRomanoMRCostagliolaC, et al.Mechanism of inflammation in age-related macular degeneration. Mediators Inflamm. 2012;2012:546786. doi:10.1155/2012/546786
10.
WangYWangVMChanCC. The role of anti-inflammatory agents in age-related macular degeneration (AMD) treatment. Eye (Lond). 2011;25(2):127–139. doi:10.1038/eye.2010.196
11.
VerittiDLanzettaP. Triple therapy for anti-vascular endothelial growth factor nonresponders in neovascular age-related macular degeneration: impact of different photodynamic therapy parameters. Ophthalmologica. 2013;230(3):131–137. doi:10.1159/000351651
12.
KovacsKDQuirkMTKinoshitaT, et al.A retrospective analysis of triple combination therapy with intravitreal bevacizumab, posterior sub-Tenon’s triamcinolone acetonide, and low-fluence verteporfin photodynamic therapy in patients with neovascular age-related macular degeneration. Retina. 2011;31(3):446–452. doi:10.1097/IAE.0b013e3181f6391f
13.
PasyechnikovaNVNaumenkoVAKorolARZadorozhnyyOSKustrinTBNasinnykIO. Serous pigment epithelium detachment associated with age-related macular degeneration: a possible treatment approach. Med Hypothesis Discov Innov Ophthalmol. 2012;1(4):72–75.
14.
AuAParikhVSSinghRP, et al.Comparison of anti-VEGF therapies on fibrovascular pigment epithelial detachments in age-related macular degeneration. Br J Ophthalmol. 2017;101(7):970–975. doi:10.1136/bjophthalmol-2016-309434
15.
BalaskasKKarampelasMHoraniMHotuOKeanePAslamT. Quantitative analysis of pigment epithelial detachment response to different anti-vascular endothelial growth factor agents in wet age-related macular degeneration. Retina. 2017;37(7):1297–1304. doi:10.1097/IAE.0000000000001342
16.
RouvasAChatziralliIAndrouA, et al.Ranibizumab versus aflibercept for the treatment of vascularized pigment epithelium detachment due to age-related macular degeneration. Int Ophthalmol. 2019;39(2):431–440. doi:10.1007/s10792-018-0833-2
17.
Castro-NavarroVCervera-TauletENavarro-PalopCMonferrer-AdsuaraCHernández-BelLMontero-HernándezJ. Intravitreal dexamethasone implant Ozurdex® in naïve and refractory patients with different subtypes of diabetic macular edema. BMC Ophthalmol. 2019;19(1):15. doi:10.1186/s12886-018-1022-9
